STOCK TITAN

Surface Oncology Inc - SURF STOCK NEWS

Welcome to our dedicated news page for Surface Oncology (Ticker: SURF), a resource for investors and traders seeking the latest updates and insights on Surface Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Surface Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Surface Oncology's position in the market.

Rhea-AI Summary
Surface Oncology (Nasdaq: SURF) reports financial results and corporate highlights for Q2 2023. Proposed merger with Coherus BioSciences expected to strengthen pipeline. Reduction in force affects 30 employees. Anticipates net cash of $20-25 million at merger closing. If merger not approved, reduced cash runway through 2023. Special Meeting of Stockholders on September 7, 2023, to approve merger. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $56.3 million. G&A expenses increased due to merger-related fees. R&D expenses decreased. Restructuring expenses of $3.2 million. Net loss for Q2 2023 was $28.2 million. Current cash and cash equivalents sufficient to fund the company through 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
earnings
-
News
Rhea-AI Summary
Coherus BioSciences has entered into a merger agreement to acquire Surface Oncology, a clinical-stage immuno-oncology company. The acquisition adds two clinical stage assets to Coherus' I-O pipeline and strengthens its position in the market. The transaction is valued at up to $65 million and is expected to close in Q3 2023. Coherus projects $48 - $53 million of net product revenue in 2Q 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.03%
Tags
acquisition
-
Rhea-AI Summary
Surface Oncology reports financial results for Q1 2023 and provides updates on clinical programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.46%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.72%
Tags
conferences clinical trial
Surface Oncology Inc

Nasdaq:SURF

SURF Rankings

SURF Stock Data

65.08M
48.80M
7.28%
46.03%
0.27%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cambridge

About SURF

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww